Each year roughly 100,000 American men hear the word cancer attached to a tumor that, on its own, may never harm them. A UCLA-led team, writing in JAMA Oncology, asks whether the name itself has grown heavier than the disease it describes. Their modeling suggests that calling the lowest-risk form of prostate cancer a precancerous condition could spare many men the fear and the unneeded treatment that follow the diagnosis, though the answer rests on how people would respond to a new word that has not yet been tried in life.
Should Lowest-Risk Prostate 'Cancer' Keep the Name? A Modeling Study Says Relabeling Could Save Lives
Men diagnosed with low-risk prostate cancer often face stress, anxiety, and treatment side effects such as urinary, bowel, and sexual dysfunction, and may lose life insurance access.
A label that may create fear or confusion
Mark
What's the basic proposal here?
Mimi
Stop calling Grade Group 1 prostate disease cancer and label it precancerous instead. The authors say it can't metastasize or cause symptoms on its own, yet up to 40% of U.S. men with it still get treated.
Mark
And the model says that saves lives?
Mimi
Nearly 2,400 a year, net. About 2,835 deaths prevented through more screening, minus about 452 added deaths from men leaving surveillance.
Luke
Careful with that. Those numbers come out of a model, not observed patients. The 2,835 depends on the assumption that relabeling actually pushes more men to get PSA tests.
Mimi
True, and the authors say so. Real-world screening behavior is exactly what still needs study.
Mark
Why would critics worry about the new label?
Mimi
If it sounds like not-cancer, men may skip biopsies and MRIs, and a tumor that turns aggressive could go unnoticed.
Luke
Is that risk actually measured?
Mimi
It's modeled as a scenario. They tested higher dropout and greater progression risk, and the net still stayed positive. Even a 3% drop in metastatic cases from screening would be enough.
Luke
Still, that's the authors' own testing of their own model. We don't yet know how a real patient hears the word precancerous.
Mark
What's the human side?
Mimi
Anxiety, treatment side effects like urinary, bowel and sexual dysfunction, and lost access to life insurance.
El Pulso
- A single word, cancer, is pulling about 100,000 men a year into fear, anxiety and surgeries they may not need.
- Up to 40% of men with the lowest-risk diagnosis end up treated, despite guidelines favoring watchful monitoring.
- Critics warn that a softer label could lead some men to abandon surveillance, letting a quiet tumor turn dangerous unseen.
- A decision model projects roughly 2,835 deaths prevented through more screening against about 452 added deaths, a net gain near 2,400 a year.
- The proposal is still a simulation, and researchers now need real-world evidence on how patients and doctors actually respond to the new name.
Each year roughly 100,000 American men hear the word cancer attached to a tumor that, on its own, may never harm them. A UCLA-led team, writing in JAMA Oncology, asks whether the name itself has grown heavier than the disease it describes. Their modeling suggests that calling the lowest-risk form of prostate cancer a precancerous condition could spare many men the fear and the unneeded treatment that follow the diagnosis, though the answer rests on how people would respond to a new word that has not yet been tried in life.
Each year about 100,000 men in the United States learn they have Grade Group 1 prostate cancer, the earliest and gentlest form of the disease, also known as Gleason 6. A UCLA-led study in JAMA Oncology now asks a pointed question: should this diagnosis carry the word cancer at all?
The biology offers the authors their starting point. A pure Grade Group 1 tumor cannot spread or produce symptoms on its own, and it typically grows slowly, if it grows at all. Guidelines favor active surveillance for nearly everyone who receives it. Yet as many as 40% of American men with this diagnosis still undergo surgery or radiation, with lasting urinary, bowel and sexual side effects. The diagnosis itself, the researchers argue, drives much of that choice through stress and fear, and it can even cost men their life insurance.
Not everyone agrees. Some specialists worry that a precancerous label would tempt patients to skip the monitoring that catches the rare tumor turning aggressive. To test that fear, the team built a decision model using U.S. population data and prior studies. They weighed deaths that might follow if fewer men stayed in surveillance against deaths avoided when more men agreed to screening, since easing worries about overdiagnosis could bring them in. In the main analysis, about 2,835 deaths were prevented each year and about 452 added, a net reduction near 2,400. The result held under harsher assumptions, and even a small screening gain would still come out ahead.
Senior author Dr. Scott Eggener of UCLA's Geffen School of Medicine compared the move to earlier redefinitions in bladder, cervical and thyroid cancer, and to a prior change in prostate cancer itself. He stressed that the proposal would not end follow-up care. The authors are candid about the limits: this is a model, not a trial, and its conclusions depend on how people would actually respond to the new name. Their next task is to see whether real patients and doctors behave as the numbers suggest.
Each year, about 100,000 men in the United States are told they have Grade Group 1 prostate cancer, the earliest and lowest-risk form of the disease. Also called Gleason 6, it is the diagnosis at the center of a new UCLA-led study in JAMA Oncology, which asks whether the word "cancer" should be attached to it at all.
The case against the label starts with the biology. A large body of research has shown that a pure GG1 tumor cannot cause symptoms or metastasize. It typically grows slowly over years or decades, or not at all, and it does not become life-threatening unless a higher-grade cancer develops in the prostate. Guidelines recommend active surveillance for nearly all men with the diagnosis: PSA testing, MRI and periodic biopsies, rather than treatment. Even so, up to 40% of men in the United States with GG1 go on to receive treatment.
The researchers point to the diagnosis itself as part of the reason. Men told they have GG1 typically experience stress and anxiety, and many choose surgery or radiation even when surveillance would be the most appropriate option. Those treatments can bring long-term urinary, bowel and sexual dysfunction. The authors also note that patients lose access to life insurance because of the cancer diagnosis, and that the label leads people to assume the disease is more dangerous than it is.
Not all experts want the label removed. Critics worry that calling GG1 a precancerous condition would lead some patients to underestimate the importance of monitoring and drop out of surveillance. If that happened, some tumors might later turn aggressive without being detected, and advanced disease and deaths could follow.
To test that concern, the team built a decision-analytical model using U.S. population data and findings from previously published studies. They estimated that about 100,000 men a year are diagnosed with GG1 and modeled what would happen if some became less likely to follow surveillance after a name change. They then weighed those potential deaths against the deaths that might be prevented if relabeling made more men willing to get PSA screening, because worries about overdiagnosis and overtreatment would ease for patients and clinicians.
In the primary analysis, relabeling prevented approximately 2,835 prostate cancer deaths annually through increased screening, while potentially causing about 452 additional deaths among patients who stopped surveillance. The net result was a reduction of nearly 2,400 deaths per year. The result held across sensitivity analyses that assumed higher rates of surveillance dropout, greater risk of progression and smaller increases in screening. Even a modest screening gain that cut metastatic prostate cancer by only 3% would still produce fewer deaths overall.
"Medicine has a history of appropriately redefining conditions when terminology no longer accurately reflects risk," said Dr. Scott Eggener, chair of urology at the David Geffen School of Medicine at UCLA and the study's senior author. He noted that similar changes have occurred in bladder, cervical and thyroid cancers, and has even happened before in prostate cancer. He stressed that the proposal does not mean ignoring these tumors or ending follow-up care.
The limits are plain. This is a mathematical model, not a study that followed patients over time, so its results depend on assumptions about how patients and physicians would respond to a new term. The authors say future research must examine real-world screening decisions, patient behavior and long-term outcomes. The first author is Dr. Andrew Vickers of Memorial Sloan Kettering; coauthors include Dr. Matthew Cooperberg and Dr. Peter Carroll of UCLA's neighbor institution UCSF, and Dr. Christian Pavlovich of Johns Hopkins.
Citas Notables
Changing the terminology does not mean ignoring these tumors or eliminating follow-up care.— Dr. Scott Eggener, UCLA
Quieres la nota completa?
Lee el original en Medical Xpress ↗
Health & Medicine